/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“ BELLUS Health ” or the “ Company ”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough,...
Biotech is expected to be a hotbed of mergers and acquisitions this year.
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health.
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
A wave of bargain buying benefited the gene therapy company's shares this week.
The company has received a buyout offer from GSK.
What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.09%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up...
GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical...
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.